360 related articles for article (PubMed ID: 28390410)
1. Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study.
Nagahori M; Kochi S; Hanai H; Yamamoto T; Nakamura S; Omuro S; Watanabe M; Hibi T;
BMC Gastroenterol; 2017 Apr; 17(1):47. PubMed ID: 28390410
[TBL] [Abstract][Full Text] [Related]
2. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis.
Lee HJ; Jung ES; Lee JH; Hong SP; Kim TI; Kim WH; Cheon JH
Hepatogastroenterology; 2012; 59(117):1415-20. PubMed ID: 22683958
[TBL] [Abstract][Full Text] [Related]
3. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
Sandborn WJ; Korzenik J; Lashner B; Leighton JA; Mahadevan U; Marion JF; Safdi M; Sninsky CA; Patel RM; Friedenberg KA; Dunnmon P; Ramsey D; Kane S
Gastroenterology; 2010 Apr; 138(4):1286-96, 1296.e1-3. PubMed ID: 20064514
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.
Prantera C; Kohn A; Campieri M; Caprilli R; Cottone M; Pallone F; Savarino V; Sturniolo GC; Vecchi M; Ardia A; Bellinvia S
Aliment Pharmacol Ther; 2009 Nov; 30(9):908-18. PubMed ID: 19678813
[TBL] [Abstract][Full Text] [Related]
5. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis.
Yen L; Wu J; Hodgkins PL; Cohen RD; Nichol MB
J Manag Care Pharm; 2012; 18(9):701-12. PubMed ID: 23206213
[TBL] [Abstract][Full Text] [Related]
6. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study.
Yokoyama H; Takagi S; Kuriyama S; Takahashi S; Takahashi H; Iwabuchi M; Takahashi S; Kinouchi Y; Hiwatashi N; Tsuji I; Shimosegawa T
Inflamm Bowel Dis; 2007 Sep; 13(9):1115-20. PubMed ID: 17455207
[TBL] [Abstract][Full Text] [Related]
7. Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis.
Piodi LP; Ulivieri FM; Cermesoni L; Cesana BM
Scand J Gastroenterol; 2004 Feb; 39(2):154-7. PubMed ID: 15000277
[TBL] [Abstract][Full Text] [Related]
8. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Sutherland L; Macdonald JK
Cochrane Database Syst Rev; 2006 Apr; (2):CD000544. PubMed ID: 16625537
[TBL] [Abstract][Full Text] [Related]
9. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Sutherland L; Roth D; Beck P; May G; Makiyama K
Cochrane Database Syst Rev; 2002; (4):CD000544. PubMed ID: 12519547
[TBL] [Abstract][Full Text] [Related]
10. Curcumin for maintenance of remission in ulcerative colitis.
Kumar S; Ahuja V; Sankar MJ; Kumar A; Moss AC
Cochrane Database Syst Rev; 2012 Oct; 10():CD008424. PubMed ID: 23076948
[TBL] [Abstract][Full Text] [Related]
11. Is maintenance therapy always necessary for patients with ulcerative colitis in remission?
Ardizzone S; Petrillo M; Imbesi V; Cerutti R; Bollani S; Bianchi Porro G
Aliment Pharmacol Ther; 1999 Mar; 13(3):373-9. PubMed ID: 10102971
[TBL] [Abstract][Full Text] [Related]
12. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Sutherland L; Macdonald JK
Cochrane Database Syst Rev; 2006 Apr; (2):CD000543. PubMed ID: 16625536
[TBL] [Abstract][Full Text] [Related]
13. The role of aminosalicylates in the treatment of ulcerative colitis.
Van Assche G; Baert F; De Reuck M; De Vos M; De Wit O; Hoang P; Louis E; Mana F; Pelckmans P; Rutgeerts P; Van Gossum A; D'Haens G
Acta Gastroenterol Belg; 2002; 65(4):196-9. PubMed ID: 12619425
[TBL] [Abstract][Full Text] [Related]
14. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
D'Haens G; Sandborn WJ; Barrett K; Hodgson I; Streck P
Am J Gastroenterol; 2012 Jul; 107(7):1064-77. PubMed ID: 22565161
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis.
Paridaens K; Fullarton JR; Travis SPL
Curr Med Res Opin; 2021 Nov; 37(11):1891-1900. PubMed ID: 34404286
[TBL] [Abstract][Full Text] [Related]
16. Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial.
Paoluzi P; D'Albasio G; Pera A; Bianchi Porro G; Paoluzi OA; Pica R; Cottone M; Miglioli M; Prantera C; Sturniolo G; Ardizzone S
Dig Liver Dis; 2002 Nov; 34(11):787-93. PubMed ID: 12546514
[TBL] [Abstract][Full Text] [Related]
17. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
Naganuma M; Iwao Y; Ogata H; Inoue N; Funakoshi S; Yamamoto S; Nakamura Y; Ishii H; Hibi T
Inflamm Bowel Dis; 2001 Aug; 7(3):221-5. PubMed ID: 11515848
[TBL] [Abstract][Full Text] [Related]
18. 2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial.
Suzuki Y; Iida M; Ito H; Nishino H; Ohmori T; Arai T; Yokoyama T; Okubo T; Hibi T
Inflamm Bowel Dis; 2017 May; 23(5):822-832. PubMed ID: 28368909
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and tolerability of once-daily mesalamine granules in the maintenance of remission of ulcerative colitis.
Lichtenstein GR; Barrett AC; Bortey E; Paterson C; Forbes WP
Inflamm Bowel Dis; 2014 Aug; 20(8):1399-406. PubMed ID: 24874460
[TBL] [Abstract][Full Text] [Related]
20. The risk factor of clinical relapse in ulcerative colitis patients with low dose 5-aminosalicylic acid as maintenance therapy: A report from the IBD registry.
Fukuda T; Naganuma M; Sugimoto S; Nanki K; Mizuno S; Mutaguchi M; Nakazato Y; Inoue N; Ogata H; Iwao Y; Kanai T
PLoS One; 2017; 12(11):e0187737. PubMed ID: 29108025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
